| Evan Douglas Peterson, PA-C | |
|
6520 Se 14th St, Des Moines, IA 50320-1846 | |
| (515) 953-1500 | |
| (515) 953-2136 |
| Full Name | Evan Douglas Peterson |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 7 Years |
| Location | 6520 Se 14th St, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003330036 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 088343 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unitypoint At Home | Urbandale, IA | Home health agency |
| Unitypoint Health - Des Moines Iowa Methodist Medi | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Physicians Clinic Medical Foundation | 8729992318 | 972 |
News Archive
Results of a Mayo Clinic survey published in the New England Journal of Medicine shows that while physicians are open to being involved in health care reform discussions, some opposition may exist.
AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that AlloWrap DS, its double-sided human amniotic membrane allograft, has been moved to the high-cost reimbursement category.
Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.
Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.
Vaccination rate figures show that older Australians are well protected against the flu but less so against pneumococcal disease and whooping cough. These figures were revealed by the Australian Institute of Health and Welfare (AIHW) and they show three-quarters of Australians aged 65 years and older had a flu shot in 2009. Just over half (55 per cent) were also vaccinated against pneumococcal disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Evan Douglas Peterson, PA-C 103 Sw 3rd St Apt 403, Des Moines, IA 50309-4832 Ph: (515) 577-6220 | Evan Douglas Peterson, PA-C 6520 Se 14th St, Des Moines, IA 50320-1846 Ph: (515) 953-1500 |
News Archive
Results of a Mayo Clinic survey published in the New England Journal of Medicine shows that while physicians are open to being involved in health care reform discussions, some opposition may exist.
AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that AlloWrap DS, its double-sided human amniotic membrane allograft, has been moved to the high-cost reimbursement category.
Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.
Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.
Vaccination rate figures show that older Australians are well protected against the flu but less so against pneumococcal disease and whooping cough. These figures were revealed by the Australian Institute of Health and Welfare (AIHW) and they show three-quarters of Australians aged 65 years and older had a flu shot in 2009. Just over half (55 per cent) were also vaccinated against pneumococcal disease.
› Verified 3 days ago
Neetha Molakala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 University Ave, Suite 120, Des Moines, IA 50314 Phone: 515-248-1500 Fax: 515-248-1510 | |
Matthew Helmick Williams, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1801 Hickman Rd, Des Moines, IA 50314 Phone: 515-282-5640 Fax: 515-282-2332 | |
Todd Eberle, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-8678 Fax: 515-643-5802 | |
Sarah Jones Ketter, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 E University Ave, Des Moines, IA 50316 Phone: 515-265-4211 | |
April Winters, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2353 Se 14th St, Des Moines, IA 50320 Phone: 515-248-1400 Fax: 515-248-1414 | |
Kelli A Roenfanz, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 East University Avenue, Des Moines, IA 50316 Phone: 515-265-4211 Fax: 515-309-5993 |